Type II Kinase Inhibitors: An Opportunity in Cancer for Rational Design

Author(s): Javier Blanc , Raphael Geney , Christel Menet .

Journal Name: Anti-Cancer Agents in Medicinal Chemistry

Volume 13 , Issue 5 , 2013

Become EABM
Become Reviewer

Abstract:

With the advent of the Type II kinase inhibitor imatinib (Gleevec) for treatment against cancer, rational design of tailored molecules has brought a revolution in medicinal chemistry for treating tumours caused by kinase malfunctioning. Among different types of kinase inhibitors, the design of Type II inhibitors has been rationalized for maximizing the benefits and reducing drawbacks. Here we highlight the development made in Type II inhibitors, discussing the advantages and disadvantages of these types of molecules. Furthermore, we present the strategies for designing druggable molecules that either selectively inhibit target kinases or overcome drug resistance.

Keywords: Allosteric inhibitors, cancer, covalent inhibitors, DFG-in, DFG-out, kinase inhibitors, Type I inhibitors, Type II inhibitors, Type III inhibitors, Type IV inhibitors.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 13
ISSUE: 5
Year: 2013
Page: [731 - 747]
Pages: 17
DOI: 10.2174/1871520611313050008
Price: $58

Article Metrics

PDF: 49